

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Evaluation of the effect of vaginal probiotic products in eliminating Human Papillomavirus in women with HPV

#### Protocol summary

##### Study aim

Investigating the effect of vaginal probiotic products in eliminating HPV virus in women

##### Design

This is a non-blinded randomized clinical trial with a parallel design and a control group. This randomized, phase 2-3 study will be conducted on at least 54 women with human papillomavirus. A simple random method is used for randomization and the participants are assigned to two intervention and control groups.

##### Settings and conduct

This study, which will be conducted at Imam Reza Hospital in Kermanshah, is non-blinded. First, a PCR test is performed for the participants in the laboratory by the resident, and high-risk patients with a positive HPV test result are included in the study.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Informed consent; Age 21-65 years; Married; Being in the follicular period of the menstrual cycle; Not having intercourse and not washing the vagina in the last 48 hours Exclusion criteria: Pregnant, lactating, and smoking women; People who are considered sick based on clinical diagnosis but whose test results are negative; Using vaginal drugs such as creams, suppositories, and vaginal disinfectants in the last 48 hours; Suffering from certain diseases such as liver, heart, kidney disease, diabetes, central nervous system diseases, blood dyscrasias, immune system defects and known sexually transmitted diseases; Use of broad-spectrum antibiotics, antiprostaglandins, hormonal and immunosuppressive drugs, alcohol, and anticoagulant drugs during the last month.

##### Intervention groups

The intervention group will receive vaginal probiotic capsules (with the trade name Lacto vag, manufactured by the American Food and Drug Company, a pack of 30), two vaginal capsules per week for 6 months. The control group will receive routine treatment.

##### Main outcome variables

wet smear

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20130812014333N200**

Registration date: **2023-05-20, 1402/02/30**

Registration timing: **prospective**

Last update: **2023-05-20, 1402/02/30**

Update count: **0**

##### Registration date

2023-05-20, 1402/02/30

##### Registrant information

##### Name

Feizollah Foroughi

##### Name of organization / entity

kermanshah University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 83 1821 4653

##### Email address

fforoughi@kums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-06-10, 1402/03/20

##### Expected recruitment end date

2024-02-09, 1402/11/20

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

## Trial completion date

empty

## Scientific title

Evaluation of the effect of vaginal probiotic products in eliminating Human Papillomavirus in women with HPV

## Public title

The effect of vaginal probiotic products in eliminating Human Papillomavirus

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Informed consent Age 21-65 years married being in the follicular period of the menstrual cycle; Not having intercourse and not washing the vagina in the last 48 hours

### Exclusion criteria:

Pregnant, lactating and smoking women People who are considered sick based on clinical diagnosis but whose test results are negative Using vaginal drugs such as creams, suppositories and vaginal disinfectants in the last 48 hours Suffering from certain diseases such as liver, heart, kidney disease, diabetes, central nervous system diseases, blood dyscrasias, immune system defects and known sexually transmitted diseases. Use of broad-spectrum antibiotics, antiprostaglandins, hormonal and immunosuppressive drugs, alcohol, and anticoagulant drugs during the last month

## Age

From **21 years** old to **65 years** old

## Gender

Female

## Phase

N/A

## Groups that have been masked

*No information*

## Sample size

Target sample size: **54**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Randomization will be done in a simple random method, after identifying eligible patients, they will be randomly assigned a three-digit dedicated code. The last digit on the right determines the patient group. If this number is 0, 1, 2, 3, 4, it will be assigned to the first intervention group, and if this number is 5, 6, 7, 8, 9, it will be assigned to the second intervention group.

## Blinding (investigator's opinion)

Not blinded

## Blinding description

### Placebo

Not used

### Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Kermanshah University of Medical Sciences

##### Street address

Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences, Building No.2, Shahid Beheshti Boulevard

##### City

Kermanshah

##### Province

Kermanshah

##### Postal code

6715847141

#### Approval date

2023-01-08, 1401/10/18

#### Ethics committee reference number

IR.KUMS.MED.REC.1402.020

## Health conditions studied

### 1

#### Description of health condition studied

human papillomavirus (HPV)

#### ICD-10 code

B97.7

#### ICD-10 code description

Papillomavirus as the cause of diseases classified elsewhere

## Primary outcomes

### 1

#### Description

wet smear

#### Timepoint

6 months after the start of the study

#### Method of measurement

Pap smear test

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

The intervention group will receive vaginal probiotic capsules (with the trade name Lacto vag, manufactured by the American Food and Drug Company, a pack of 30), two vaginal capsules per week for 6 months

#### Category

Treatment - Drugs

## 2

### Description

The control group will receive routine treatment

### Category

Treatment - Other

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Emam Reza Hospital

##### Full name of responsible person

Dr. saba Najafi

##### Street address

Emam Reza Hospital, Parastar Boulevard

##### City

Kermanshah

##### Province

Kermanshah

##### Postal code

6715847141

##### Phone

+98 83 3427 6306

##### Email

saba.najafi.k@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Kermanshah University of Medical Sciences

##### Full name of responsible person

Dr. Cyrus Jalili

##### Street address

Vice Chancellor for Research Affairs, Kermanshah  
University of Medical Sciences, Building No.2, Shahid  
Beheshti Boulevard

##### City

Kermanshah

##### Province

Kermanshah

##### Postal code

6715847141

##### Phone

+98 83 3836 0014

##### Email

cjalili@kums.ac.ir

##### Grant name

##### Grant code / Reference number

##### Is the source of funding the same sponsor organization/entity?

Yes

##### Title of funding source

Kermanshah University of Medical Sciences

##### Proportion provided by this source

100

##### Public or private sector

Public

##### Domestic or foreign origin

Domestic

##### Category of foreign source of funding

empty

##### Country of origin

##### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Kermanshah University of Medical Sciences

##### Full name of responsible person

Dr. Saba Najafi

##### Position

Resident of Obstetrics and Gynecology

##### Latest degree

Medical doctor

##### Other areas of specialty/work

Gynecology and Obstetrics

##### Street address

Emam Reza Hospital, Parastar Boulevard

##### City

Kermanshah

##### Province

Kermanshah

##### Postal code

6715847141

##### Phone

+98 83 3427 6306

##### Email

saba.najafi.k@gmail.com

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Kermanshah University of Medical Sciences

##### Full name of responsible person

Dr. Maryam Zangeneh

##### Position

Member of the faculty of Kermanshah University of  
Medical Sciences

##### Latest degree

Specialist

##### Other areas of specialty/work

Gynecology and Obstetrics

##### Street address

Imam Reza Hospital, School of Medicine, parastar  
boulvarde

##### City

Kermanshah

##### Province

Kermanshah

##### Postal code

6714415153

##### Phone

+98 83 3426 6780

##### Email

mzangeneh@kums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

Dr. Saba Najafi

**Position**

Resident of Obstetrics and Gynecology

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Emam Reza Hospital, Parastar Boulevard

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6715847141

**Phone**

6715847141

**Email**

saba.najafi.k@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no further information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available